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OBJECTIVE—To examine the longitudinal association of fat
mass– and obesity-associated (FTO) variant with obesity, circu-
lating adipokine levels, and FTO expression in various materials
from human and mouse.
RESEARCH DESIGN AND METHODS—We genotyped
rs9939609 in 2,287 men and 3,520 women from two prospective
cohorts. Plasma adiponectin and leptin were measured in a
subset of diabetic men (n  854) and women (n  987).
Expression of FTO was tested in adipocytes from db/db mice and
mouse macrophages.
RESULTS—We observed a trend toward decreasing associa-
tions between rs9939609 and BMI at older age (65 years) in
men, whereas the associations were constant across different age
groups in women. In addition, the single nucleotide polymor-
phism (SNP) rs9939609 was associated with lower plasma adi-
ponectin (log[e] means, 1.82  0.04, 1.73  0.03, and 1.68 
0.05 for TT, TA, and AA genotypes, respectively; P for trend 
0.02) and leptin (log[e] means, 3.56  0.04, 3.63  0.04, and
3.70  0.06; P for trend  0.06) in diabetic women. Adjustment
for BMI attenuated the associations. FTO gene was universally
expressed in human and mice tissues, including adipocytes. In an
ancillary study of adipocytes from db/db mice, FTO expression
was 50% lower than in those from wild-type mice.
CONCLUSIONS—The association between FTO SNP rs9939609
and obesity risk may decline at older age. The variant affects
circulating adiponectin and leptin levels through the changes in
BMI. In addition, the expression of FTO gene was reduced in
adipocytes from db/db mice. Diabetes 57:3145–3151, 2008
I
n a recent genome-wide association study, Frayling
et al. (1) identiﬁed a common variant in fat mass–
and obesity-associated (FTO) gene (rs9939609) that
was related to higher BMI in both children and
adults. In addition, adiposity appeared to mediate the
association between FTO variant and the risk of type 2
diabetes (2,3). Several other studies have also observed
associations between FTO variants and obesity-related
traits in various populations (4–13).
Because most available data are cross-sectional, the
longitudinal pattern of the associations between FTO
variants and adiposity and age-speciﬁc genetic effects are
not clearly deﬁned. The primary aim of the present study
is to address these issues by assessing the genetic effects
in two prospective cohorts. Obesity status affects the
endocrine function of adipose tissue by altering the secre-
tion of adipokines, such as adiponectin and leptin, which
have been related to ectopic fat accumulation, insulin
sensitivity, and diabetes risk in epidemiological studies
(14–16). We therefore examined the associations of FTO
variant with circulating levels of adiponectin and leptin. In
addition to the association analyses, to shed light on its
potential functions, we also examined the expression of
FTO gene in various tissues from humans and mice and
investigated the expression in adipocytes from db/db mice
and mice macrophages in response to inﬂammatory
stimulants.
RESEARCH DESIGN AND METHODS
The Nurses’ Health Study (NHS) was established in 1976 when 121,700 female
registered nurses aged 30–55 years and residing in 11 large U.S. states
completed a mailed questionnaire on their medical history and lifestyle (17).
Between 1989 and 1990, 32,826 women provided blood samples. The Health
Professional Follow-Up Study (HPFS) is a prospective cohort study of 51,529
U.S. male health professionals aged 40–75 years at study initiation in 1986
(18). Between 1993 and 1999, 18,159 men provided blood samples. Information
about health and disease is assessed biennially by self-administered question-
naires in both cohorts.
Diabetes cases were deﬁned as self-reported diabetes conﬁrmed by a
validated supplementary questionnaire. For cases occurring before 1998, the
diagnosis was made using criteria proposed by the National Diabetes Data
Group (19). Medical record review conﬁrmed 98% of the diagnoses. We used
the American Diabetes Association diagnostic criteria for diagnosis after the
1998 cycles (20). Subjects for the present study were selected from those who
provided blood samples and were free from cardiovascular disease or cancer
at baseline. Healthy control subjects were matched on age and the time of
blood drawing with diabetic patients. To reduce potential bias due to
population stratiﬁcation, we included only Caucasians of European ancestry.
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1,211 male nondiabetic control subjects were included.
Assessment of adiposity. At baseline (1976 for the NHS and 1986 for the
HPFS), participants were asked to report their height and current body
weight; the self-reported weight was then updated every 2 years during the
follow-up through 2002 (1976, 1978, 1980, 1982, 1986, 1988, 1990, 1992, 1994,
1996, 1998, 2000, and 2002 in the NHS; and 1986, 1988, 1990, 1992, 1994, 1996,
1998, 2000, and 2002 in the HPFS) using self-administered questionnaires. To
assess the adiposity in early adulthood, the 1980 NHS questionnaire asked
about weight at 18 years of age (n  3,337), and the 1986 HPFS questionnaire
asked about weight at 21 years of age (n  2,194). We calculated BMI as
weight in kilograms divided by height squared in meters. In 1986–1987,
participants in the NHS (n  2,333) and HPFS (n  1,898) reported direct
measurements of their waists (at the umbilicus) and hips (at the largest
circumference) to the nearest quarter of an inch, using a paper tape and
detailed measuring directions. The validity of self-reported adiposity mea-
sures were assessed in a random sample living in the greater Boston area, with
high correlation with measured weight (r  0.96) and waist (r  0.95) (21,22).
We deﬁned obesity as BMI 30 kg/m
2.
Assessment of biomarkers. Blood samples were collected between 1989
and 1990 in NHS and between 1993 and 1999 in HPFS, as previously described
(23,24). Biomarkers were measured in a subset of diabetic men (n  854) and
women (n  987). Plasma adiponectin concentration was measured by
competitive radioimunoassay (RIA; Linco Research, St. Charles, MO) with a
coefﬁcient of variation (CV) of 3.4%. Leptin was assayed by RIA (Linco
Research) with intra-assay CV of 3.4–8.3%. A1C values were determined based
on turbidimetric immunoinhibition using hemolyzed whole blood or packed
red cells. The day-to-day variability at A1C concentrations of 5.5 and 9.1% was
1.9 and 3.0%, respectively.
Single nucleotide polymorphism selection and genotype determination.
To date, ﬁve single nucleotide polymorphisms (SNPs) in FTO genes have been
reported to be associated with obesity traits. These SNPs are in strong to
perfect linkage disequilibrium. We therefore selected one SNP, rs9939609,
which was found by the ﬁrst genome-wide association (GWA) study, as a
proxy for other SNPs (pairwise r
2 with rs9939609: rs17817449, 1.00; rs1421085,
0.97; rs3751812, 1.00; and rs9930506, 0.84; HapMap, Centre d’Etude du
Polymorphisme Humain [CEPH]). DNA was extracted from the buffy coat
fraction of centrifuged blood using the QIAmp Blood kit (Qiagen, Chatsworth,
CA). The SNP was genotyped using TaqMan SNP allelic discrimination by
means of an ABI 7900HT (Applied Biosystems, Foster City, CA). The internal
quality of genotype data was assessed by typing 10% blinded samples in
duplicate; resulting concordance was 99%. The call rate was 95%, and
genotype distribution was in Hardy-Weinberg equilibrium (
2 test).
Real-time RT-PCR and analyses of experimental data. Mouse tissues
were collected from wild-type (n  3; C57BL/6 strain mice obtained from The
Jackson Laboratories [Bar Harbor, ME]) and db/db mice (n  3, 3 months old,
male), a genetic model of obesity and type 2 diabetes. Mouse 3T3-L1
adipocytes were differentiated in media containing insulin, dexamethasone,
and isobutylmethylxanthine for 8 days. Human adipocytes were differentiated
from preadipocytes (obtained from a cell line maintained by Cambrex) in a
similar manner. Mouse macrophages were generated from bone marrow of
wild-type mice as described previously (25). Macrophages were cultured in
Dulbecco’s modiﬁcation of Eagle’s medium and 10% fetal bovine serum and
treated with -interferon (IFN-) at a dose of 2 ng/ml overnight. Lipopolysac-
charide (LPS; 10 ng/ml) was then added for an additional 8 h. RNA was
isolated using TRIzol (Invitrogen) and reverse transcribed with the Quantitect
RT kit (Qiagen). Human tissue (brain, heart lung, liver, spleen, intestine,
kidney, muscle, leukocytes, preadipocytes, and adipocytes) cDNAs were
purchased from Clontech (multiple choice cDNA). SYBR green–based real-
time PCRs were conducted using RealMasterMix (Eppendorf) and detected by
the 7300 Real-Time PCR system (Applied Biosystems). The expression of the
36B4 gene, which is a housekeeping gene to serve as a control, was used for
normalization to obtain relative expression levels. The slope of efﬁciency
curves for human FTO gene is 3.4 and for mouse is 3.6 (4 means PCR
product doubles each cycle). Oligo sequences used were as follows: human FTO,
5-TTTAGTTCCACCCACCGAGT-3 and 5-ACATTCTGCAGAGCCAACTG-3;
mouse FTO,5 -ATCACGATGAGAACCTGGTG-3 and 5-CCAACATGCCAAG-
TATCAGG-3; and 36B4, 5-AGATGCAGCAGATCCGCAT-3 and 5-GTTCTT-
GCCCATCAGCACC-3.
For gene expression analyses, values are presented as means  SE (n  3),
and group means were compared using Student’s t test. The SAS statistical
package was used for the analyses (SAS, version 8.2 for UNIX). Statistical
signiﬁcance was set at the 0.05 level, and all tests were two-tailed.
Statistical analyses. Similar associations between FTO SNP rs9939606 and
BMI were previously reported in diabetic patients and control subjects (1) and
were also observed in our cohorts. Thus, we pooled diabetic and nondiabetic
subjects in the analyses. The geometric means of BMI and waist circumfer-
ence were compared among the genotypes using general linear models,
adjusting for age and diabetes status. In the multivariable analyses, we also
adjusted for physical activity (quintiles), smoking (never, past, and current),
alcohol intake (nondrinker and drinker [0.1–4.9, 5–10, or 10 g/day]), family
history of diabetes (yes/no), and menopausal status (pre- or postmenopausal
[never, past, or current hormone use]; women only). Crude associations
between genotype and binary outcomes (obesity and diabetes) were tested
using Pearson’s 
2 statistic, and unconditional logistic regression was used to
test for association after adjusting for covariates. General linear models were
used to compare the genotype difference in biomarkers (adiponectin and
leptin) among diabetic patients, adjusting for age, BMI, physical activity,
smoking, alcohol intake, duration of diabetes, A1C, and menopausal status
(women only). Plasma adiponectin and leptin levels were logarithmically
transformed to achieve a normal distribution. The geometric means of the
back-transformed values were presented.
We used generalized estimating equations (GEEs) to analyze the associa-
tions between the genotypes and longitudinal BMI values (26,27). The analysis
used the biennially collected repeated measurements of BMI from 1976 to
2002 in the NHS and from 1986 to 2002 in the HPFS. We used exchangeable
correlation structure to account for the correlation of the repeated measures.
Interaction between genotype and age was tested by creating a product term
of the two variables in the model.
RESULTS
Table 1 shows the baseline characteristics of the partici-
pants by sex and diabetes status. The frequency of
rs9939609 allele A in the study populations was 0.44,
similar to the HapMap population frequency of 0.45 in the
CEPH and other European populations (1,4).
Associations with adiposity at early and middle
adulthood. Table 2 shows the associations of SNP
rs9939609 with BMI (n  2,236 and 3,483 in men and
women, respectively) and waist circumference (n  1,898
and 2,333 in men and women, respectively) in 1986/1987,
when both measures were available in the NHS and HPFS,
and with BMI at early adulthood (n  2,194 and 3,337 in
men and women, respectively). The SNP was associated
TABLE 1
Baseline characteristics of the men and women from the HPFS and NHS
Characteristics
Men (HPFS) Women (NHS)
Diabetic Nondiabetic Diabetic Nondiabetic
Participants (n) 1,076 1,211 1,506 2,014
Age (years) 56  85 5  94 4  74 4  7
Physical activity* 14.7  19.0 21.5  28.1 3.6  2.8 4.1  2.9
Alcohol consumption (g/day) 11.4  16.8 12.3  15.5 4.1  8.3 6.4  9.8
Smoking 11.0 7.0 28.9 21.8
Family history of diabetes 32.3 12.6 52.5 22.7
Data are n, means  SD, and percent. Cohort baseline, 1976 for the NHS and 1986 for HPFS; physical activity and alcohol consumption were
obtained from the 1980 questionnaire in NHS. *In hours of physical activity of at least moderate intensity per week for women and in MET
hours per week for men.
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an additive inheritance model. In men, rs9939609 was
associated with a higher BMI. SNP rs9939609 was also
associated with higher BMI at early adulthood in men and
women (Table 2). Although the genetic effects in men
seemed not to ﬁt well with the additive model, testing for
the departure from the additive model was not signiﬁcant.
Because smoking may affect adiposity, we excluded cur-
rent smokers in sensitivity analyses but did not ﬁnd
appreciable changes in the associations.
We further assessed the relation between rs9939609 and
obesity risk (in 1986/1987). The AA homozygotes were
associated with 1.75 (1.26–2.45) and 1.71 (1.36–2.16) times
higher obesity risk in men and women, respectively (Fig.
1). Because few people were obese (2.6% in men and 3.4%
in women) at early adulthood, we examined the associa-
tions between FTO genotypes and the risk of overweight
(BMI 25 kg/m
2) instead. In both men and women, the AA
homozygotes were associated with 1.57 (1.22–2.03) and
1.84 (1.40–2.40) times higher overweight risk in men and
women at early adulthood (Fig. 1).
Associations with longitudinal measurements of adi-
posity. rs9939609 was associated with higher BMI during
the 26 years of follow-up in women (1976–2002) and was
associated with BMI at nearly all time points during 16
years of follow-up in men (1986–2002) except in 1988 and
1998 (supplementary Fig. 1, which is available in an online
appendix at http://dx.doi.org/10.2337/db08-0006). Simi-
larly, the AA genotype was associated with greater obesity
risk during the follow-up in women and men (except at
1992, 1996, and 2000 in men) (supplementary Fig. 2).
In longitudinal analyses using GEEs, associations were
observed between rs9939609 and BMI and the obesity risk
in both sexes (Table 3). Each allele A was associated with
0.25 (SE  0.11; P  0.03) and 0.59 (SE  0.13; P 	 0.0001)
kg/m
2 higher BMI, as well as 1.21 (1.05–1.38)–fold (P 
0.007) and 1.19 (1.07–1.31)–fold (P  0.0008) higher risk of
obesity in men and women, respectively. We further
examined whether the associations between SNP
rs9939609 and adiposity were consistent across different
age groups (Figs. 2 and 3). It appears that the association
between the SNP and obesity risk declined with older age
especially in men, although tests for interaction between
genotypes and age were not signiﬁcant (P  0.20 for men
and 0.08 for women).
Case-control studies on type 2 diabetes. In the crude
analyses, the TA and AA genotypes were associated,
respectively, with a 1.17 (1.01–1.36)–fold and 1.24 (1.02–
1.50)–fold higher risk of type 2 diabetes compared with the
TT genotype in women (P for trend  0.019) (Table 4). The
associations between FTO genotypes and diabetes risk
became nonsigniﬁcant when adjusted for BMI. However,
adjusting for other diabetes risk factors, such as age,
smoking, alcohol consumption, and physical activity, did
not alter the association for diabetes. This SNP was not
associated with diabetes risk in men.
Associations with adipokine concentrations in pa-
tients with type 2 diabetes. We further assessed
whether FTO SNP rs9939609 was associated with adipose-
secreted adipokines. We measured leptin and adiponectin
in a subset of patients with type 2 diabetes (987 women
and 854 men). In women, the FTO genotypes were asso-
TABLE 2
BMI and waist circumference (in cm) according to rs9939609 genotypes
n
Mean measures by genotypes P values P values
per allele TT TA AA TA vs. TT AA vs. TA AA vs. TT
Men 2,287 34* 48* 18*
BMI (kg/m
2), age 21 2,194 23.1  3.0 23.1  3.0 23.8  3.2 0.94 0.0001 0.0002 0.0007
BMI (kg/m
2), 1986
All subjects 2,236 26.2  3.7 26.3  3.6 26.7  4.0 0.45 0.05 0.01 0.02
Nonsmoker 2,042 26.2  3.8 26.3  3.5 26.7  4.0 0.58 0.18 0.09 0.09
Waist circumference, 1987
All subjects 1,898 97.7  10.4 98.0  10.0 98.4  10.8 0.44 0.55 0.23 0.12
Nonsmoker 1,740 97.6  10.4 97.9  9.8 98.3  10.8 0.39 0.68 0.28 0.14
Women 3,520 34* 46* 20*
BMI (kg/m
2), age 18 3,337 21.7  3.3 21.9  3.5 22.5  3.7 0.06 0.0009 	0.0001 	0.0001
BMI (kg/m
2), 1986
All subjects 3,483 26.8  5.6 27.4  5.9 28.2  6.1 0.008 0.0099 	0.0001 	0.0001
Nonsmoker 2,624 26.9  5.6 27.5  5.9 28.3  6.2 0.019 0.008 	0.0001 	0.0001
Waist circumference, 1986
All subjects 2,333 82.8  13.1 83.9  13.3 85.2  14.3 0.27 0.12 0.02 0.02
Nonsmoker 2,007 82.7  13.0 83.8  13.1 85.4  14.4 0.19 0.10 0.01 0.01
Data are means  SD. Except for early adulthood (men, age 21; and women, age 18), analyses were adjusted for age and diabetes status.
*Overall percentage of each genotype.
FIG. 1. Odds ratios (ORs) of overweight (BMI >25 kg/m
2) at early
adulthood and obesity (BMI >30 kg/m
2) in 1986 associated with the TA
and AA genotypes of the FTO SNP rs9939609 (T>A) compared with the
AA genotype in men and women. Risk was adjusted for age and diabetes
status. Error bars denote 95% CIs.
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transformed means: 1.82  0.04, 1.73  0.03, and 1.68 
0.05 for TT, TA, and AA genotypes, respectively; P  0.02),
adjusting for age (Fig. 4). The association remained when
adjusted for smoking, alcohol consumption, physical ac-
tivity, duration of diabetes, A1C, and menopausal status.
Further adjustment for BMI attenuated the association.
Allele A tended to be associated with higher leptin levels,
with borderline signiﬁcance. The genotype-associated dif-
ference in leptin disappeared when adjusted for BMI. In
men, we did not ﬁnd associations between FTO genotypes
and adipokine levels.
FTO gene expression proﬁle and in tissues/cells with
high metabolic capacities. To shed light on its potential
role in adiposity, we conducted expression proﬁling of the
FTO gene in human and mouse tissues and found similar
expression patterns between the two species (supplemen-
tary Fig. 3). FTO was present at high levels in several
metabolically active tissues (from humans and wild-type
C56BL/6 mice), including brain, heart, kidney, and adipose
tissue, with the highest expression in brain from humans
and mice. In white adipose tissue isolated from db/db
mice, FTO expression was reduced by 50% compared
with lean wild-type controls (Fig. 5A). Interestingly, FTO is
also expressed by macrophages and was induced by
inﬂammatory stimulants, IFN-, and LPS (Fig. 5B).
DISCUSSION
In this study, we conﬁrmed that the SNP rs9939609 was
associated with higher BMI and obesity risk (1) in men and
women from two independent U.S. cohorts. Frayling et al.
(1) observed that the FTO genotype–associated difference
in BMI occurred as early as 7 years old. We observed
associations between FTO SNP and high BMI in early
adulthood. The genetic effects were constant across dif-
ferent ages in women but tended to decrease at older ages
in men. The mechanisms underlying this observation are
not clear. A longitudinal twin study suggests that the
TABLE 3
GEE analyses on the associations between rs9939609 and BMI and obesity in men (1986–2002) and women (1976–2002)
TT TA AA Per allele P values
Men
BMI (kg/m
2) 26.5  3.9 26.5  3.8 27.1  4.4 0.25 (0.02–0.47) 0.03
Obesity 1.0 1.13 (0.90–1.41) 1.47 (1.12–1.92) 1.21 (1.05–1.38) 0.007
Women
BMI (kg/m
2) 26.9  5.6 27.5  6.0 28.3  6.3 0.59 (0.34–0.84) 	0.0001
Obesity 1.0 1.06 (0.90–1.24) 1.46 (1.20–1.77) 1.19 (1.07–1.31) 0.0008
Data are means  SD or OR (95% CI).
FIG. 2. The geometric means of BMI by the genotypes of FTO SNP
rs9939609 in different age groups among men (<50, 50–54.9, 55–59.5,
60–64.9, 65–69.9, and >70 years old) (A) and women (<45, 45–49.5,
50–54.9, 55–59.5, 60–64.9, 65–69.9, and >70 years old) (B). The
analyses were adjusted for diabetes status. *P < 0.05.
FIG. 3. ORs of obesity associated with the TA and AA genotypes of FTO
SNP rs9939609 compared with TT genotype in different age groups of
men (<50, 50–54.9, 55–59.5, 60–64.9, 65–69.9, and >70 years old) (A)
and women (<45, 45–49.5, 50–54.9, 55–59.5, 60–64.9, 65–69.9, and >70
years old) (B). The analyses were adjusted for diabetes status. Error
bars denote 95% CIs.
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throughout life (28) and decrease with advanced age
(29,30). Adiposity loss with age may partly explain the
reduction in association at senior age. In addition, envi-
ronmental inﬂuences accumulate with age and likely exert
stronger inﬂuences on later BMI. It appears that the
decreasing trend of BMI with advanced age is more
pronounced in men than in women, but the test for
interaction between sex and FTO was not statistically
signiﬁcant.
In women, rs9939609 was associated with greater risk of
type 2 diabetes. Adjustment for BMI abolished the associ-
ation. This ﬁnding is consistent with the observations from
recent GWA studies (2,3), supporting the idea that obesity
mediates the effects of FTO variant on the development of
type 2 diabetes.
Adipose tissue acts as endocrine organ through secret-
ing hormone-like adipokines, which mediate the effects of
obesity on various metabolic disorders (31). Adiponectin
is the most abundant adipokine in the circulation (32).
Adiponectin improves insulin action and metabolism of
glucose and lipids (33,34). Low blood adiponectin levels
have been related to increased risk of obesity and diabetes
(35,36). Our data indicated that low adiponectin levels
associated with the risk allele A were secondary to the
changes in BMI and may partly mediate the genetic effects
on diabetes risk. The association between FTO SNP and
adiponectin was observed in diabetic patients. Future
studies are warranted to replicate the ﬁndings in the
general population.
Little is known about the function of FTO gene. Our data
comparing both human and mouse genes conﬁrm high
expression of FTO gene in brain (1). Gerken et al. (37)
recently demonstrated that FTO was highly expressed in
arcuate, paraventricular, dosomedial, and ventromedial
nuclei. Of note, all of these sites are of critical importance
in controlling energy balance. These data suggest FTO
gene may affect the neuroregulation of energy balance. In
addition, FTO expression was high in heart, kidney, and
adipose tissues (particularly brown fat in mice).
The expression of FTO was moderately increased in
adipocytes compared with preadipocytes and was sub-
stantially reduced in white adipose tissues of obese,
diabetic db/db mice, indicating that it may play a role in
adipocyte function but not adipogenesis. The mechanism
underlying the reduced expression of FTO in adipocytes
from the genetic models with direct interruptions of the
TABLE 4
Associations between rs9939609 genotypes and the risk of type 2 diabetes in men and women
Diabetic Nondiabetic Model 1 P values Model 2 P values Model 3 P values
Men (n  2,287)
TT 362 (33.6) 406 (33.5) 1.0 1.0
TA 486 (45.2) 556 (45.9) 0.98 (0.81–1.18) 0.83 0.95 (0.78–1.17) 0.64 0.95 (0.78–1.16) 0.64
AA 228 (21.2) 249 (20.6) 1.03 (0.82–1.29) 0.82 0.94 (0.73–1.21) 0.63 0.99 (0.78–1.26) 0.94
Women (n  3,520)
TT 484 (32.1) 726 (36.0) 1.0 1.0 1.0
TA 739 (49.1) 944 (46.9) 1.17 (1.01–1.36) 0.036 1.08 (0.92–1.27) 0.33 1.21 (1.03–1.43) 0.019
AA 283 (18.8) 344 (17.1) 1.24 (1.02–1.50) 0.034 1.02 (0.83–1.26) 0.84 1.26 (1.03–1.56) 0.029
Data are n (%) and OR (95% CI). Model 1, crude analysis; model 2, adjusted for BMI; model 3, adjusted for other covariates than BMI, including
age, physical activity (quintiles), smoking (never, past, and current), alcohol intake (nondrinker and drinker 
0.1–4.9, 5–10, or 10 g/day),
family history of diabetes, and menopausal status (pre- or postmenopausal 
never, past, or current hormone use; for women only).
FIG. 4. The geometric means (SEs) of plasma adiponectin and leptin
levels (log-transformed) by the genotypes of FTO SNP rs9939609
among women with type 2 diabetes. The multivariate analyses were
adjusted for age, physical activity (quintiles), smoking (never, past,
and current), alcohol intake (nondrinker and drinker [0.1–4.9, 5–10, or
>10 g/day]), duration of diabetes, A1C, and menopausal status (pre- or
postmenopausal [never, past, or current hormone use]).
FIG. 5. Regulation of FTO expression by genetic obesity and inﬂam-
matory stimulants. A: FTO is downregulated in adipose tissue of db/db
mice. Adipose tissue was harvested from lean wild-type (n  3) and
obese, diabetic db/db mice (n  3), and gene expression was deter-
mined by real-time RT-PCR. B: FTO is induced by proinﬂammatory
stimulants in the macrophages. Bone marrow–derived wild-type mouse
macrophages were incubated with or without 2 ng/ml IFN- overnight
followed by 10 ng/ml LPS treatment for 8 h. The experiments were done
in triplicate. *P < 0.05.
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FTO is likely a part of the pathway mediating the neuro-
regulation (e.g., leptin) of energy metabolism in adi-
pose tissue, and blocking the leptin signal may inhibit the
downstream changes in adipose tissue that induce the
expression of FTO. Furthermore, FTO was found to be
expressed in leukocytes and was drastically upregulated in
macrophages stimulated with IFN- and LPS. Given that
metabolic dysregulation is recognized as a state of chronic
inﬂammation (38,39), it is possible that FTO is a molecular
link between metabolism and inﬂammation in the patho-
genesis of obesity-related metabolic diseases.
SNP rs9939609 is highly correlated with many other
SNPs within a 47-kb region encompassing parts of the ﬁrst
two introns and exon 2 of FTO gene. Sequencing the
chromosomes did not result in clear candidate functional
variants in the FTO coding region, minimal splice sites, or
3-untranslated region (1). Further work is warranted to
explore the genetic mechanism underpinning the observed
associations.
Several limitations need to be acknowledged. Population
stratiﬁcation, mostly arising from either ethic admixture or
genetic substructure within an ethnically homogenous group,
may cause spurious associations. However, neither is likely
to explain the associations observed in the present study.
Our study populations are highly homogeneous by including
only European whites. In addition, there is no evidence
showing regional difference in rs9939606 across European
countries (1).
The participants in our study do not represent random
samples of U.S. men and women. However, major cohort
studies, such as the Framingham Heart Study, have also
not relied on national samples. Clearly, data validity is the
chief prerequisite that must be fulﬁlled before the results
can be generalized. In previous analyses, the observed
genetic and environmental associations for obesity, type 2
diabetes, coronary heart disease, and other diseases in our
cohorts are very similar to those found in other broadly
based U.S. populations (40–44). Nonetheless, the ﬁndings
in the present study need to be replicated in other ethnic
groups.
Adiposity measures were self-reported in our cohorts.
However, self-reported information has been reliably val-
idated, with a high correlation with technician-measured
variables (21,22). In addition, previous analyses in NHS
and HPFS have demonstrated that self-reported BMI and
waist circumference strongly predicted various chronic
diseases (40,45,46).
We examined only one SNP, rs9939609, which was
reported by the original GWA study (1). Several other
SNPs were associated with obesity in subsequent studies
(4,5), but these SNPs are all in strong to perfect linkage
disequilibrium with rs9939609. Thus, genotyping of these
SNPs would have been redundant.
In conclusion, we conﬁrmed associations between the
FTO SNP rs9939609 and higher obesity risk. Our data
suggest that the genetic association for obesity may de-
cline at older age. In addition, the genetic variant may
affect circulating adiponectin levels through the changes
in BMI. The expression of FTO gene was reduced in
adipocytes from db/db mice. Little is known about the
function of FTO gene, and thus, further investigation is
warranted to identify the causal genetic variants and
potential mechanisms underlying the observed genetic
associations.
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